Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Probenecid is an FDA approved drug for the treatment gout and hyperuricemia. It has been used safely in humans for decades for this and other indications. The investigators have recently discovered that this drug can also stimulate other receptors in the heart and therefore improve its function. The hypothesis of this study is that probenecid can be used to improve the function of the heart and therefore the symptoms in patients with heart failure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cincinnati
• Treatments: Probenecid

Criteria

Inclusion Criteria

1. 18 years of age or older

2. EF < 40% via echocardiogram within the past 12 months

3. Stable dose of heart failure medications for > past 1 month

4. NYHA class II - IV

Exclusion Criteria

1. Pregnant or lactating female

2. Receiving IV inotrope

3. History of significant non-compliance

4. Unwilling to adhere to the protocol

5. Systemic systolic BP less than 90 mmHg at screening visit

6. History of allergy to probenecid

7. History of gout

8. History of renal calculi

9. Recent unstable coronary artery syndromes (USA, admission to hospital for AMI, revascularization procedure, or acute decompensated HF requiring hospitalization) within the past 3 months.

10. Implant of CRT device within the past 3 months

11. TIA, CVA or major surgery within the past 3 months

12. Valvular heart disease (more than moderate stenosis or insufficiency)

13. HOCM, myocarditis, constrictive pericarditis, congenital heart disease, 14 Active chemotherapy, significant malignancy or uncontrolled metabolic disease (untreated hyper or hypothyroidism, Cushing's disease etc.)What about uncontrolled DM?? HgA1C > etc

15. Elevated liver enzymes (> 3 times ULN), 16. Current atrial fibrillation or frequent PVCs (should we define this now) 17. End stage renal disease (dialysis dependent) or worsening renal insufficiency should define now.

18. History of gastric ulcerations, significant gastroesophageal reflux. 19. Other condition that in the opinion of the investigator, would make the subject a poor candidate for the study.

20. Co-administration of any medication that in the opinion of the investigator places the subject at increased risks due to potential adverse drug interactions.